There are 412 resources available
290P - Adverse events (AEs) and impact on quality of life (QoL) of antibody-drug conjugates (ADC) in the treatment of metastatic breast cancer (mBC): A systematic review and meta-analysis of randomized controlled trials (RCTs)
Presenter: Marta Perachino
Session: Lunch and Poster Display session
291P - Perceptions of antibody drug conjugate (ADC)-induced nausea and vomiting: Results of a survey of healthcare providers at ESMO
Presenter: Giampaolo Bianchini
Session: Lunch and Poster Display session
292P - Association between adverse childhood events and baseline cognitive functioning in patients with localized breast cancer
Presenter: Ayelet Shai
Session: Lunch and Poster Display session
293P - Evaluating chemotherapy side effects in Moroccan breast cancer patients and introducing an AI mobile health app for remote support: A comprehensive approach
Presenter: Farah Choulli
Session: Lunch and Poster Display session
294P - Breast cancer patient driven research agenda developed for and by breast cancer patients
Presenter: Marjolein Scholten
Session: Lunch and Poster Display session
295P - Climate change impact and sustainability: A survey of Breast International Group (BIG) members
Presenter: Seamus O'Reilly
Session: Lunch and Poster Display session
297P - Modified Delphi consensus on interventions for radiation dermatitis in breast cancer: A Canadian expert perspective
Presenter: Tarek Hijal
Session: Lunch and Poster Display session
Welcome, introduction, and goal setting
Presenter: Stephen Johnston
Session: PeerView Oncology - supported by Lilly - Safeguarding patients with HR+, HER2-, high-risk, early breast cancer: A practical roadmap for CDK4/6 inhibition in the adjuvant setting
Resources:
Webcast
Conducting risk assessment in HR+, HER2- EBC to identify patients at high risk of recurrence
Presenter: Joyce O'Shaughnessy
Session: PeerView Oncology - supported by Lilly - Safeguarding patients with HR+, HER2-, high-risk, early breast cancer: A practical roadmap for CDK4/6 inhibition in the adjuvant setting
Resources:
Webcast
Integrating latest evidence and guideline recommendations to support multifactorial clinical decisions about use of adjuvant CDK4/6 inhibition in high-risk, HR+, HER2- EBC
Presenter: Stephen Johnston
Session: PeerView Oncology - supported by Lilly - Safeguarding patients with HR+, HER2-, high-risk, early breast cancer: A practical roadmap for CDK4/6 inhibition in the adjuvant setting
Resources:
Webcast